Key Facts GPs Should Know About GLP-1 Analogs
Family Medicine Initiative
APRIL 9, 2024
Yes, one year after stopping the medication, patients regain ½ – ⅔ of their previous weight loss: What are other clinical benefits? In March 2024, FDA therefore approved semaglutide for secondary CVD prevention in overweight or obese adults. Tirzepatide (15 mg) showed slightly more noticeable effects than Semaglutide (2.4
Let's personalize your content